Gastrointestinal Research Bundle x 9 Vials (KPV 10mg / BPC-157 10mg / VIP 5mg)

The gut wall can be read in layers, and each peptide in this set enters at a different one. KPV, at just three residues, can enter intestinal epithelial cells and act on inflammatory signalling inside them, so it stands for the lining cell’s own response. VIP is released by enteric neurons and binds VPAC receptors on epithelial, smooth-muscle and immune cells, so it stands for the nervous system’s input to secretion, motility and inflammation. BPC-157’s gastrointestinal work has centred on mucosal integrity, lesion healing and blood-vessel responses. That gives a combined model three separate entry points and lets hypotheses be framed precisely: does neural VPAC signalling add anything once epithelial inflammatory signalling is already damped, and does either change how quickly a damaged mucosa recovers?

The colitis evidence behind each peptide was gathered in different systems. The KPV papers that put it on the map used dextran sodium sulfate (DSS) and T-cell transfer colitis in mice; the VIP study above used TNBS-induced colitis in mice; and most of BPC-157’s gut literature comes from rat work by one Zagreb group. We are not aware of any published study testing two or all three of these peptides together. In practice, each one needs its own response curve in your chosen model before a combination arm means anything. The choice of model matters too: DSS injures the epithelium chemically and suits barrier questions, while TNBS produces a hapten-driven, T-cell-led inflammation, so picking one effectively decides which bundle member is tested on home ground.

In culture, Caco-2 or T84 monolayers give transepithelial electrical resistance and tracer flux for barrier function, IL-8 release after a cytokine challenge for epithelial inflammation, and scratch-wound closure for restitution. VIP brings a classic readout of its own: it stimulates chloride secretion in T84 monolayers, measurable as short-circuit current in an Ussing chamber, which confirms that the VIP arm is actually engaging its receptor. In rodent colitis models the standard panel of disease-activity score, colon length, histology and myeloperoxidase activity applies to all three. Reading every arm on every measure is what turns three single-peptide experiments into a genuine comparison of how the layers interact.

Equal milligrams mean very different numbers of molecules here. KPV’s 10mg fill (roughly 342.4 g/mol) amounts to about 29 micromoles, a 10mg BPC-157 vial (about 1,419.5 g/mol) about 7 micromoles, and a 5mg VIP vial (about 3,325.8 g/mol) around 1.5 micromoles, so the KPV vial carries about four times the molecules of BPC-157 and nearly twenty times those of VIP. Comparisons between arms are therefore best set on a molar basis. VIP is also the most delicate of the three, quickly cut by peptidases and carrying an oxidation-prone methionine, so the three VIP vials suit a one-vial-per-run pattern: each experimental series starts from freshly opened material instead of a solution kept for weeks.